By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Austrian biomarker firm Biocrates and Canadian firm Chenomx have signed a co-marketing pact, under which the firms will combine their technologies to generate metabolic profiling tools for monitoring the effects of disease, nutrition, toxins, environment, or drugs on an organism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.